Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

10

Possibly Marketed Outside US

2

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Phosphodiesterase 10A

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

11

2013

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Schizophrenia

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Takeda Pharmaceutical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

13

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

13

FDA UNII

13

PUBCHEM

13

EPA CompTox

12

ECHA (EC/EINECS)

11

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

9

Salts, Hydrates, Esters, etc.

4

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 13 results

First page disabled
Previous page disabled
1
Next page
Next page

BALIPODECT

6650W303H0

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Phosphodiesterase 10A

Conditions:

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 0.30 nM; >15000-fold selectivity over other PDEs. TAK-063 is currently being evaluated in clinical trials for the treatment of schizophr...

enia. Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.

Pinacol

527QE7I5CO

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

2-Aminobenzonitrile

5RXH2B211R

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

M-TOLUIDINE

006FKQ96T3

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

4-METHYLBENZENAMINE

I1D0KL7I4U

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

M-ANISIDINE

JXA144KX2I

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

2-Chloroaniline

G14I494T2F

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

2-HYDRAZINOETHANOL

8T2Z8Z231F

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

M-AMINOPHENOL

L3WTS6QT82

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2013

Class (Stereo):

CHEMICAL (ACHIRAL)

PINACOL HEXAHYDRATE

01906GQ23R

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Showing 1 - 10 of 13 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1